Ind-Swift Laboratories (NSE:INDSWFTLAB) Total Operating Expense: ₹2,616 Mil (TTM As of Mar. 2026)


NSE:INDSWFTLAB Ind-Swift Laboratories Ltd NSE:INDSWFTLAB
55 GF Score
Price ₹221.74
GF Value ₹36.93
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Ind-Swift Laboratories Total Operating Expense?

Ind-Swift Laboratories NSE:INDSWFTLAB +3.54% 55 Total Operating Expense is ₹2,616 Mil as of Mar. 2026. GuruFocus rates NSE:INDSWFTLAB with a GF Score™ of 55/100 and a GF Value™ of ₹36.93 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Ind-Swift Laboratories's Total Operating Expense for the three months ended in Mar. 2026 was ₹959 Mil. Ind-Swift Laboratories's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was ₹2,616 Mil.

Ind-Swift Laboratories Total Operating Expense Related Terms

Ind-Swift Laboratories Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Ind-Swift Laboratories's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ind-Swift Laboratories Total Operating Expense Chart

Ind-Swift Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,171.90 2,589.26 4,699.90 3,176.29 3,443.51

Ind-Swift Laboratories Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 795.88 971.63 804.96 852.71 958.62
NSE:INDSWFTLAB
55GF Score
Ind-Swift Laboratories Ltd NSE:INDSWFTLAB
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ind-Swift Laboratories Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹2,616 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of ₹2,616 Mil mean?
Ind-Swift Laboratories (NSE:INDSWFTLAB) has a Total Operating Expense of ₹2,616 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Ind-Swift Laboratories and its competitors.
Is Ind-Swift Laboratories' Total Operating Expense too high?
Ind-Swift Laboratories' current Total Operating Expense is ₹2,616 Mil. Overall, Ind-Swift Laboratories has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ind-Swift Laboratories' Total Operating Expense compare to ZTS and UTHR?
Ind-Swift Laboratories' Total Operating Expense of ₹2,616 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Drug Manufacturers company?
A good Total Operating Expense depends on the Drug Manufacturers industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Ind-Swift Laboratories and its competitors. Ind-Swift Laboratories's current Total Operating Expense is ₹2,616 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ind-Swift Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Ind-Swift Laboratories (NSE:INDSWFTLAB) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹36.93, compared to a current price of ₹221.74 — trading 500.4% above its estimated fair value. The current Total Operating Expense is ₹2,616 Mil. Ind-Swift Laboratories' overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Ind-Swift Laboratories (NSE:INDSWFTLAB), the current Total Operating Expense is ₹2,616 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ind-Swift Laboratories (NSE:INDSWFTLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Ind-Swift Laboratories stock appears to be overvalued. The current stock price of ₹221.74 is trading 500.4% above its estimated GF Value™ of ₹36.93. GuruFocus considers Ind-Swift Laboratories to be Significantly Overvalued.

Key valuation signals for NSE:INDSWFTLAB:

  • Total Operating Expense: ₹2,616 Mil
  • GF Value™: ₹36.93 vs. price of ₹221.74 (500.4% above fair value)
  • GF Score™: 55/100 with 4 warning signs

No single metric tells the full story. See the NSE:INDSWFTLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ind-Swift Laboratories Business Description

Other Exchanges 532305:India
Address SCO 850, NAC, Shivalik Enclave, Manimajra, Chandigarh, PB, IND, 160101
Ind-Swift Laboratories Ltd is involved in manufacturing Active Pharmaceutical Ingredients (API), Intermediates, and formulations. The company serves various therapeutic segments, including Cardiovascular health, Antihistamines, Antidiabetics, Antipsychotics, Parkinson's disease, Antineoplastics, ADHD Symptoms, Analgesics, Alcohol Abstinence, and Bone Resorption Inhibitors. It operates solely in the pharmaceutical products sector. Geographically, the company supplies both domestic and international markets, with the majority of its revenue coming from outside India.
55GF Score

Get the complete analysis for NSE:INDSWFTLAB

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹221.74
Price
₹36.93
GF Value